Exploring the Inflammatory Metabolomic Profile to Predict Response to TNF-α Inhibitors in Rheumatoid Arthritis

In clinical practice, approximately one-third of patients with rheumatoid arthritis (RA) respond insufficiently to TNF-α inhibitors (TNFis). The aim of the study was to explore the use of a metabolomics to identify predictors for the outcome of TNFi therapy, and study the metabolomic fingerprint in active RA irrespective of patients’ response. In the metabolomic profiling, lipids, oxylipins, and amines were measured in serum samples of RA patients from the observational BiOCURA cohort, before start of biological treatment. Multivariable logistic regression models were established to identify predictors for good- and non-response in patients receiving TNFi (n = 124). The added value of metabolites over prediction using clinical parameters only was determined by comparing the area under receiver operating characteristic curve (AUC-ROC), sensitivity, specificity, positive- and negative predictive value and by the net reclassification index (NRI). The models were further validated by 10-fold cross validation and tested on the complete TNFi treatment cohort including moderate responders. Additionally, metabolites were identified that cross-sectionally associated with the RA disease activity score based on a 28-joint count (DAS28), erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). Out of 139 metabolites, the best-performing predictors were sn1-LPC(18:3-ω3/ω6), sn1-LPC(15:0), ethanolamine, and lysine. The model that combined the selected metabolites with clinical parameters showed a significant larger AUC-ROC than that of the model containing only clinical parameters (p = 0.01). The combined model was able to discriminate good- and non-responders with good accuracy and to reclassify non-responders with an improvement of 30% (total NRI = 0.23) and showed a prediction error of 0.27. For the complete TNFi cohort, the NRI was 0.22. In addition, 88 metabolites were associated with DAS28, ESR or CRP (p<0.05). Our study established an accurate prediction model for response to TNFi therapy, containing metabolites and clinical parameters. Associations between metabolites and disease activity may help elucidate additional pathologic mechanisms behind RA.

[1]  O. Madsen.  Stability of clinical outcome measures in rheumatoid arthritis patients with stable disease defined on the basis of the EULAR response criteria , 2016, Clinical Rheumatology.

[2]  J. Bijlsma,et al.  Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability. , 2016, Rheumatology.

[3]  Monica Guma,et al.  Metabolomics in rheumatic diseases: desperately seeking biomarkers , 2016, Nature Reviews Rheumatology.

[4]  N. Ohte,et al.  Serotonin in peripheral blood reflects oxidative stress and plays a crucial role in atherosclerosis: Novel insights toward holistic anti-atherothrombotic strategy. , 2016, Atherosclerosis.

[5]  A. Ząbek,et al.  Application of (1)H NMR-based serum metabolomic studies for monitoring female patients with rheumatoid arthritis. , 2016, Journal of pharmaceutical and biomedical analysis.

[6]  M. Valerio,et al.  1H-NMR-Based Metabolomic Study for Identifying Serum Profiles Associated with the Response to Etanercept in Patients with Rheumatoid Arthritis , 2015, PloS one.

[7]  G. Savoye,et al.  Polyunsaturated fatty acids and inflammation , 2015, IUBMB life.

[8]  J. Branco,et al.  DAS28, CDAI and SDAI cut-offs do not translate the same information: results from the Rheumatic Diseases Portuguese Register Reuma.pt. , 2015, Rheumatology.

[9]  A. Koulman,et al.  A Review of Odd-Chain Fatty Acid Metabolism and the Role of Pentadecanoic Acid (C15:0) and Heptadecanoic Acid (C17:0) in Health and Disease , 2015, Molecules.

[10]  M. Giera,et al.  Prolonged niacin treatment leads to increased adipose tissue PUFA synthesis and anti-inflammatory lipid and oxylipin plasma profile[S] , 2014, Journal of Lipid Research.

[11]  M. Fischer,et al.  Alterations of Plasma Lysophosphatidylcholine Species in Obesity and Weight Loss , 2014, PloS one.

[12]  K. Kim,et al.  Global Metabolite Profiling of Synovial Fluid for the Specific Diagnosis of Rheumatoid Arthritis from Other Inflammatory Arthritis , 2014, PloS one.

[13]  Helena Canhão,et al.  FRI0298 The Impact of DMARD Co-Therapy on Abatacept Effectiveness in Rheumatoid Arthritis Patients. A Pan-European Analysis of RA Registries , 2014 .

[14]  E. Gibney,et al.  Relationship between the lipidome, inflammatory markers and insulin resistance. , 2014, Molecular bioSystems.

[15]  H. Burkhardt,et al.  Development and Validation of a New Disease Activity Score in 28 Joints–Based Treatment Response Criterion for Rheumatoid Arthritis , 2013, Arthritis care & research.

[16]  M. Valerio,et al.  Metabolomics in rheumatic diseases: the potential of an emerging methodology for improved patient diagnosis, prognosis, and treatment efficacy. , 2013, Autoimmunity reviews.

[17]  M. Fitzpatrick,et al.  Metabolic Profiling Predicts Response to Anti–Tumor Necrosis Factor α Therapy in Patients With Rheumatoid Arthritis , 2013, Arthritis and rheumatism.

[18]  T. Hankemeier,et al.  Quantitative profiling of oxylipins through comprehensive LC-MS/MS analysis: application in cardiac surgery , 2012, Analytical and Bioanalytical Chemistry.

[19]  E. Kontny,et al.  Taurine and inflammatory diseases , 2012, Amino Acids.

[20]  M. Rogero,et al.  Does Branched-Chain Amino Acids Supplementation Modulate Skeletal Muscle Remodeling through Inflammation Modulation? Possible Mechanisms of Action , 2012, Journal of nutrition and metabolism.

[21]  Nguyen Dang Hung,et al.  Prevention of 1-palmitoyl lysophosphatidylcholine-induced inflammation by polyunsaturated acyl lysophosphatidylcholine , 2012, Inflammation Research.

[22]  Lx Wang,et al.  1H NMR-based metabolomic study of metabolic profiling for systemic lupus erythematosus , 2011, Lupus.

[23]  T. Hankemeier,et al.  Metabolomics of cerebrospinal fluid reveals changes in the central nervous system metabolism in a rat model of multiple sclerosis , 2011, Metabolomics.

[24]  T. Hankemeier,et al.  Metabolomics of cerebrospinal fluid reveals changes in the central nervous system metabolism in a rat model of multiple sclerosis , 2011, Metabolomics.

[25]  David T Felson,et al.  UvA-DARE (Digital Academic Repository) American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials , 2011 .

[26]  N. Jewell,et al.  To GEE or Not to GEE: Comparing Population Average and Mixed Models for Estimating the Associations Between Neighborhood Risk Factors and Health , 2010, Epidemiology.

[27]  Terry K. Smith,et al.  The Kennedy pathway—De novo synthesis of phosphatidylethanolamine and phosphatidylcholine , 2010, IUBMB life.

[28]  Laure Gossec,et al.  Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis , 2010, Annals of the rheumatic diseases.

[29]  John Wong,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs , 2010, Annals of the rheumatic diseases.

[30]  J. Meulman,et al.  Equating, or correction for between-block effects with application to body fluid LC-MS and NMR metabolomics data sets. , 2010, Analytical chemistry.

[31]  Frans M van der Kloet,et al.  Analytical error reduction using single point calibration for accurate and precise metabolomic phenotyping. , 2009, Journal of proteome research.

[32]  J. Kabarowski.  G2A and LPC: regulatory functions in immunity. , 2009, Prostaglandins & other lipid mediators.

[33]  S. Gabriel,et al.  Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases , 2009, Arthritis research & therapy.

[34]  Takao Shimizu,et al.  Acyl-CoA:Lysophospholipid Acyltransferases* , 2009, Journal of Biological Chemistry.

[35]  T. Hankemeier,et al.  RPLC-ion-trap-FTMS method for lipid profiling of plasma: method validation and application to p53 mutant mouse model. , 2008, Journal of proteome research.

[36]  X. Ye.  Lysophospholipid signaling in the function and pathology of the reproductive system. , 2008, Human reproduction update.

[37]  M. Uffmann,et al.  Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score , 2005, Arthritis research & therapy.

[38]  E. Keystone,et al.  Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. , 2004, Arthritis and rheumatism.

[39]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[40]  P. Tugwell,et al.  A simplified disease activity index for rheumatoid arthritis for use in clinical practice. , 2003, Rheumatology.

[41]  A. Silman,et al.  Epidemiology and genetics of rheumatoid arthritis , 2002, Arthritis research.

[42]  J. Volanakis,et al.  Human C-reactive protein: expression, structure, and function. , 2001, Molecular immunology.

[43]  J. Frostegård,et al.  Lysophosphatidylcholine (LPC) induces proinflammatory cytokines by a platelet‐activating factor (PAF) receptor‐dependent mechanism , 1999, Clinical and experimental immunology.

[44]  J. Kremer,et al.  A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. , 1999, The New England journal of medicine.

[45]  P. van Riel,et al.  Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. , 1998, Arthritis and rheumatism.

[46]  J. Ghrayeb,et al.  Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. , 1993, Arthritis and rheumatism.

[47]  R. Chakrabarti,et al.  Adaptive regulation in skeletal muscle glutamine metabolism in endotoxin-treated rats. , 1992, The Journal of trauma.

[48]  J. Fischer,et al.  Cytokines and glucocorticoids in the regulation of the "hepato-skeletal muscle axis" in sepsis. , 1991, American journal of surgery.

[49]  I. Ginsburg,et al.  Lysophosphatides enhance superoxide responses of stimulated human neutrophils , 1989, Inflammation.

[50]  J. Kellgren,et al.  The epidemiology of rheumatoid arthritis: a review. II. Incidence and diagnostic criteria. , 1968, Bulletin on the rheumatic diseases.

[51]  B. Hammock,et al.  Mass spectrometry-based metabolomics. , 2007, Mass spectrometry reviews.

[52]  M. Prevoo,et al.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[53]  Robert C. Wolpert,et al.  A Review of the , 1985 .

[54]  W. Youden,et al.  Index for rating diagnostic tests , 1950, Cancer.